Categories
Change Password!
Reset Password!
Over time, there has been a reduction in the excessive reporting of allergies, and this decline has not impacted adherence to anti-SARS-CoV-2 vaccination.
In a report stemming from Israel, where a national COVID-19 vaccination initiative was launched in December 2020, attention was drawn to the occurrence of allergic reactions linked to the Pfizer-BioNTech BNTT162B2 vaccine. This communication was derived from an extensive national registry and offered an exclusive perspective on allergic incidents occurring during vaccination efforts. It meticulously outlined the variations in how reports of such events were submitted over time, while also delving into the distinctive attributes and the credibility of the documented allergic reactions.
The backdrop for this analysis was the global context of sporadic cases of severe allergic responses recorded in other nations, raising initial concerns about vaccine safety. The primary aim of the study was to comprehensively understand and describe incidents of allergic reactions in response to COVID-19 vaccines. Methodologically, the study harnessed data collected by healthcare professionals across Israel, who reported instances of allergic events through an online national vaccine registry managed by the Israeli Ministry of Health Division of Epidemiology.
The data collection period spanned from December 19, 2020, to September 13, 2021, during which an impressive 14,475,979 vaccine doses were administered. The findings of the research highlighted that out of a total of 463 subjects who experienced allergic reactions, a staggering 99.3% had received the Pfizer-BioNTech BNTT162B2 vaccine. Notably, the incidence rate of allergic reactions was notably higher in December 2020, standing at 106 cases per million administered doses.
However, this number exhibited a decreasing trend in subsequent months, plummeting to 66, 18, 14, eight, and ultimately zero cases per million doses from January to September 2021. Key demographics outlined in the study indicated that the average age of affected individuals was approximately 48.9 years, with females accounting for 78% of the reported cases. Intriguingly, only a small fraction of cases (8%) were validated as immediate allergies, suggesting a mere 2.5 to 3.3 authentic allergic reactions per million doses.
In instances where reactions were classified as severe (n=46), the study identified plausible allergy as a contributing factor in 36% to 41% of cases. Importantly, the study also highlighted that individuals with a history of allergies were more likely to incorrectly report immediate reactions (83% false reporting rate). Encouragingly, the data indicated that experiencing an allergic event after the initial vaccine dose did not hinder individuals from following through with subsequent doses.
In conclusion, the research established a decline in the prevalence of excessive allergy reporting over time, and notably, such reports did not hinder adherence to vaccination schedules. While a history of allergies influenced reporting tendencies, it was found not to impact the occurrence of vaccine-related allergic reactions. This study thus contributes valuable insights into the dynamics of allergic reactions following COVID-19 vaccination, helping to shape a more comprehensive understanding of vaccine safety.
The Journal of Allergy and Clinical Immunology
Reporting of Allergic Reactions During Pfizer-BioNTech BNTT162B2 Vaccination in Israel
Emilia Anis et al.
Comments (0)